# **Health Products Regulatory Authority**

# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Zarontin 250mg/5ml Syrup

#### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 5 ml contains 250 mg ethosuximide.

#### **Excipients with known effect:**

Each 5 ml contains 3 g sucrose, 5 mg glucose, 12 mg sodium benzoate (E211) and 42 mg propylene glycol (E1520).

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Syrup.

Product imported from Belgium.

A clear, slightly yellowish to slightly pinkish, dye-free, raspberry flavoured syrup.

#### **4 CLINICAL PARTICULARS**

As per PA22644/005/001

#### **5 PHARMACOLOGICAL PROPERTIES**

As per PA22644/005/001

#### **6 PHARMACEUTICAL PARTICULARS**

#### 6.1 List of excipients

Sodium citrate

Sodium benzoate (E211)

Saccharin sodium

Sucrose

Glycerol

Raspberry flavour including (contains glucose and propylene glycol (E 1520))

Citric acid monohydrate

Purified water

#### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf life expiry date for this product shall be the date shown on the bottle and outer package of the product on the market in the country of origin.

#### 6.4 Special precautions for storage

Do not store above 25°C

09 January 2024 CRN00DWQW Page 1 of 2

# **Health Products Regulatory Authority**

#### 6.5 Nature and contents of container

Amber glass bottle with child-resistant cap. Each unit contains 200 ml and is placed in folding carton with a measuring cup graduated 15 ml.

## 6.6 Special precautions for disposal and other handling

No special requirements.

#### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Originalis B.V. Joop Geesinkweg 901 1114 AB Amsterdam-Duivendrecht Netherlands

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA2306/031/001

# 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 5<sup>th</sup> January 2024

10 DATE OF REVISION OF THE TEXT

09 January 2024 CRN00DWQW Page 2 of 2